Cargando…

Targeting EZH2 Promotes Chemosensitivity of BCL-2 Inhibitor through Suppressing PI3K and c-KIT Signaling in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is one of the most common hematological malignancies with high heterogeneity, characterized by a differentiating block at the early progenitor stage. The selective BCL-2 inhibitor, Venetoclax (Ven), has shown exciting clinical results in a certain group of AML patients....

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Chan, Gu, Yan, Ge, Zheng, Song, Chunhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569949/ https://www.ncbi.nlm.nih.gov/pubmed/36232694 http://dx.doi.org/10.3390/ijms231911393

Ejemplares similares

Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia
por: Jiang, Xuejie, et al.
Publicado: (2021)

Dual roles of EZH2 in acute myeloid leukemia
por: Skoda, Radek C., et al.
Publicado: (2019)

Clinical Significance of EZH2 in Acute Myeloid Leukemia
por: Jiao, Weiyun, et al.
Publicado: (2022)

Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2022)

Retracted: Clinical Significance of EZH2 in Acute Myeloid Leukemia
por: Intelligence and Neuroscience, Computational
Publicado: (2023)

Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms
por: Zhang, Qi, et al.
Publicado: (2019)

EZH2 in Myeloid Malignancies
por: Rinke, Jenny, et al.
Publicado: (2020)

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Cysteine‐rich protein 61 regulates the chemosensitivity of chronic myeloid leukemia to imatinib mesylate through the nuclear factor kappa B/Bcl‐2 pathway
por: Song, Yanfang, et al.
Publicado: (2019)

Expression of Enhancer of Zeste Homolog 2 (EZH2) Gene in Acute Myeloid Leukemia
por: Hamed, Nahla A. M., et al.
Publicado: (2023)

Long noncoding RNA HOXA-AS2 functions as an oncogene by binding to EZH2 and suppressing LATS2 in acute myeloid leukemia (AML)
por: Feng, Yubin, et al.
Publicado: (2020)

Nucleophosmin Mutations Induce Chemosensitivity in THP-1 Leukemia Cells by Suppressing NF-κB Activity and Regulating Bax/Bcl-2 Expression
por: Zhang, Shuaishuai, et al.
Publicado: (2016)

Corrigendum: Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?
por: Kulsoom, Bibi, et al.
Publicado: (2018)

Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia
por: Wang, Jingyi, et al.
Publicado: (2020)

Coexistence of EZH2, NOTCH1, IL7R, and PHF6 Mutations in Adult T-cell Acute Lymphoblastic Leukemia
por: Zhou, Xilian, et al.
Publicado: (2017)

BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia
por: Zhou, Jing-dong, et al.
Publicado: (2019)

Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia
por: Wei, Wenwen, et al.
Publicado: (2022)

ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors
por: Rehman, Hasibur, et al.
Publicado: (2022)

Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells
por: Cornet-Masana, Josep Maria, et al.
Publicado: (2016)

Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia
por: Campos, Elisabete do Vale, et al.
Publicado: (2019)

The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells
por: Opydo-Chanek, Małgorzata, et al.
Publicado: (2020)

ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia
por: Ebner, Jessica, et al.
Publicado: (2023)

Expanding dasatinib beyond KIT in acute myeloid leukemia
por: Welch, John S.
Publicado: (2020)

Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin
por: Han, Yixiang, et al.
Publicado: (2015)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

Mutational mechanisms of EZH2 inactivation in myeloid neoplasms
por: Chase, Andrew, et al.
Publicado: (2020)

Myeloid Ezh2 Deficiency Limits Atherosclerosis Development
por: Neele, Annette E., et al.
Publicado: (2021)

Are BCL6 and EZH2 novel therapeutic targets for systemic lupus erythematosus?
por: Ding, Shu, et al.
Publicado: (2022)

Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia
por: Megías-Vericat, Juan Eduardo, et al.
Publicado: (2019)

Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation
por: Opydo, Małgorzata, et al.
Publicado: (2023)

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia
por: Lewis, Alexander C., et al.
Publicado: (2022)

Ikaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia
por: Ge, Zheng, et al.
Publicado: (2016)

Acute Myeloid Leukemia Cells Harboring MLL Fusion Genes or with the Acute Promyelocytic Leukemia Phenotype Are Sensitive to the Bcl-2-selective Inhibitor ABT-199
por: Niu, Xiaojia, et al.
Publicado: (2014)

Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia
por: Murray, Heather C., et al.
Publicado: (2023)

Small Molecule Inhibitors of Microenvironmental Wnt/β-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia
por: Takam Kamga, Paul, et al.
Publicado: (2020)

Coordinate PI3K pathway and Bcl-2 family disruption in AML
por: Bose, Prithviraj, et al.
Publicado: (2012)

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

Combined BCL-2 and PI3K/AKT Pathway Inhibition in KMT2A-Rearranged Acute B-Lymphoblastic Leukemia Cells
por: Holz, Clemens, et al.
Publicado: (2023)

Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
por: Zhao, Jianyun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ckgpurhcvn4en5leptv2u0mb4l